麻豆传媒

Meeting Coverage >

ESC

Low-Dose DOAC Valuable in Afib After Age 80

Randomized trial suggests benefit on par with warfarin in younger groups

Impressive Results With Early-Rhythm Control in AFib

Results from EAST-AFNET 4 trial "should and will change practice," expert says

Novel Tx Turns in Favorable Performance in Obstructive HCM

Mavacamten tackles underlying pathophysiology of hypertrophic cardiomyopathy

Second SGLT2 Drug Scores for HFrEF, Regardless of Diabetes Status

EMPEROR-Reduced trial "exceptionally concordant" with DAPA-HF results

Post-MI Survival Better With ICD for Some, Troubled Trial Suggests

Potential benefit in STEMI survivors with severe LV dysfunction, other risk factors soon after PCI

Precision Medicine Lowers DAPT Bleeds in STEMI

Trial also hits noninferiority mark for adverse cardiac events

SYNTAX at 10 Years: Bypass vs PCI Still a Toss-Up Overall

But CABG beats stenting for important subgroups

MITRA-FR Inches in Line With COAPT at 2 Years Despite Contradictory Findings

More evidence that the two trials are more concordant than previously thought

Bariatric Surgery Tied to Better Cardiometabolic Health Down the Road

Improvements beyond risk factor reduction in patients with T2D and obesity

Antiplatelets Go Head-to-Head in ACS, With Unexpected Result

Assumption that ticagrelor would be superior upended in ISAR-REACT 5

Big Cuts in LDL Possible With Twice-Yearly Injections

siRNA may make for a more convenient lipid-lowering therapy for patients

Dapagliflozin Benefits HFrEF Outcomes, Even Without Diabetes

DAPA-HF trial affirms similar benefit to diabetes drug regardless of type 2 diabetes status

Risk-Based Thresholds for hs-Troponin I Safely Speed MI Rule-Out

HISTORIC suggests benefit to patients, clinicians

Extended DAPT with Brilinta: No Benefit for Stable CAD in T2D

Substudy in those with prior PCI might identify group where bleeding tradeoff is worthwhile

COMPLETE Revascularization Gets Its Win for Hard Outcomes

Investigators obtain missing piece of the puzzle

Entresto Signals Expansion Into 'Gray Zone' of HFpEF

PARAGON-HF may have missed overall, but HF docs see reason for hope

Drive LDL as Low as Possible, ESC Says

New guideline emphasizes more intensive reduction across risk groups

ESC: Evidence Grows for HFpEF as Microvascular Disease

Studies on exact mechanisms, potential targets still needed

ESC: DCB Works for De Novo Stenoses in Small Coronary Vessels

Established for in-stent restenosis, DCBs make their way to native coronary arteries

ESC: Oral Antibiotics Safe for Stable Endocarditis

Switching after a period of IV antibiotics didn't raise event rates in POET trial

ESC: ACS Outcomes the Same for High-Sensitivity vs Standard Troponin Tests

No reduction in later events with more sensitive assay

ESC: PURE Buries Controversy, Advocates for 'Balanced Diet'

But dairy and red meat levels still differ from guidelines

ESC: Interatrial Shunting Safe in HFpEF, Pivotal Trial to Come

Device eases left-sided filling pressure, but to what clinical significance?

ESC: MI Redefined in International Guidelines

Fourth "Universal Definition of Myocardial Infarction" issued

ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac Amyloidosis

Plus clear advantage seen in 6-minute walk test

ESC: Xarelto Fails to Change Outcomes in Heart Failure

No death or hospitalization reduction seen in COMMANDER-HF

ESC: Short DAPT with Ticagrelor Doesn't Improve Outcomes

Antiplatelet strategy safe, but misses superiority to standard DAPT after stenting

ESC: MitraClip Fails in Functional Mitral Regurgitation

No impact on hard outcomes in MITRA-FR randomized trial

ESC: Aspirin Holds Little Net Benefit for Primary CV Prevention

'No compelling evidence' emerges in two randomized trials

ESC: Omega-3 Supplements No Better Than Olive Oil for CV Risk

1-g dose disappoints in ASCEND trial

ESC: Weight-Loss Drug Clears Major CV Hurdle

Trial also shows modest reduction in new cases of diabetes

ESC: Rivaroxaban Doesn't Prevent VTE after Acute Illness

Efficacy shown in prior trial is lost, but safety gained in this setting

ESC: Restrictive Transfusion Deemed Safe in Cardiac Surgery Patients

Restrictive strategy superior in those ages ≥75, according to TRICS III trial

ESC: Telemonitoring of HF Cuts Admissions, Mortality

Remote patient management program works in German trial

ESC: CTA for Stable Chest Pain Prevents More MIs Long Term

Better than stress ECG as first-line test, SCOT-HEART investigators say

Primary Prevention Headlines at ESC

Will aspirin, fish oil pan out in big trials?

ESC: Top Videos from This Year's Meeting

Highlights include CANTOS history and a Houston cardiologist's take on the flood

ESC: Yusuf, Lloyd-Jones Square Off Over Diet Guidelines

PURE not going to change AHA fat recommendations?

ESC: 1-Hour NSTEMI Rule-Out 'Very Safe' in Study

ESC's algorithm validated with high negative predictive values

ESC Roundup: IMPACT-AF; ORION-1; Swedish Registry

Three studies of note

3